1형 당뇨병(T1D) : 7개 시장 의약품 예측과 시장 분석

This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the type 1 diabetes market through 2033.

GlobalData estimates sales of T1D therapeutics to be approximately $2.83 billion across the 7MM in 2023. By 2033, GlobalData expects the T1D market to grow at a strong compound annual growth rate (CAGR) of 13.3%, reaching sales of $9.91 billion by the end of the forecast period.

Major drivers of T1D market growth over the forecast period are the -

• Increase in the prescription of rapid-acting insulins in line with rising use of insulin pumps
• Launch of several oral and injectable agents, particularly immunomodulatory therapies
• Increase in the global prevalence of T1D

Major barriers that will restrict the growth of the T1D market during the forecast period are the -

• High price of certain insulins and immunomodulatory agents
• Patent expiries allowing for further biosimilar and generic erosion
• High failure rate of clinical trials developing disease-modifying therapeutics

Scope

• Overview of type 1 diabetes, including epidemiology, symptoms, diagnosis, and disease management.
• Annualized type 1 diabetes therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the type 1 diabetes therapeutics market.
• Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for type 1 diabetes treatment. The most promising candidates in late-stage development are profiled.
• Analysis of the current and future market competition in the global type 1 diabetes therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the 7MM type 1 diabetes therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM type 1 diabetes therapeutics market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Type 1 Diabetes: Executive Summary

• 1.1 Type 1 Diabetes therapeutics market will grow to $9.91 billion by 2033
• 1.2 T1D market leaders employ diverse strategies to protect insulin franchises from biosimilar threats, while emerging players focus on disease-modifying innovations
• 1.3 Persistent unmet needs highlight gaps in current and emerging T1D therapies
• 1.4 The synergistic rise of pumps, CGMs, and ultra-rapid-acting insulins in T1D management
• 1.5 What do physicians think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related reports
• 2.3 Upcoming reports

3 Disease Overview

• 3.1 Etiology and pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology
  • 3.1.3 Biomarkers for monitoring the islet autoreactivity of T1D

4 Epidemiology

• 4.1 Disease background
• 4.2 Risk factors and comorbidities
• 4.3 Global and historical trends
• 4.4 7MM forecast methodology
  • 4.4.1 Sources
  • 4.4.2 Forecast assumptions and methods
  • 4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of T1D - 7MM
  • 4.4.4 Forecast assumptions and methods: diagnosed prevalent cases of T1D
  • 4.4.5 Diagnosed prevalent cases of T1D segmented by BMI
  • 4.4.6 Diagnosed prevalent cases of T1D that experienced hypoglycemic events
  • 4.4.7 Diagnosed prevalent cases of T1D with brittle diabetes
  • 4.4.8 Diagnosed prevalent cases of T1D that experienced DKA events
  • 4.4.9 Diagnosed prevalent cases of T1D eligible for pancreas transplantation
  • 4.4.10 Diagnosed prevalent cases of T1D with CKD
  • 4.4.11 Diagnosed prevalent cases of T1D with CVD
  • 4.4.12 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
  • 4.4.13 Forecast assumptions and methods: total prevalent cases of T1D
• 4.5 Epidemiological forecast for T1D (2023-33)
  • 4.5.1 Diagnosed prevalent cases of T1D
  • 4.5.2 Age-specific diagnosed prevalent cases of T1D
  • 4.5.3 Sex-specific diagnosed prevalent cases of T1D
  • 4.5.4 Diagnosed prevalent cases of T1D by BMI category
  • 4.5.5 Diagnosed prevalent cases of T1D that experienced hypoglycemic events
  • 4.5.6 Diagnosed prevalent cases of T1D with brittle diabetes
  • 4.5.7 Diagnosed prevalent cases of T1D that experienced DKA events
  • 4.5.8 Diagnosed prevalent cases of T1D eligible for pancreas transplantation
  • 4.5.9 Diagnosed prevalent cases of T1D with CKD
  • 4.5.10 Diagnosed prevalent cases of T1D with CVD
  • 4.5.11 Diagnosed prevalent cases of T1D with at least one gene encoding for HLA-DQ8
  • 4.5.12 Total prevalent cases of T1D
• 4.6 Discussion
  • 4.6.1 Epidemiological forecast insight
  • 4.6.2 COVID-19 impact
  • 4.6.3 Limitations of the analysis
  • 4.6.4 Strengths of the analysis

5 Disease Management

• 5.1 Diagnosis and treatment overview
• 5.2 US disease management
• 5.3 5EU disease management
• 5.4 Japan disease management
• 5.5 KOL insights on disease management

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Urgent need for disease-modifying therapies
• 7.3 Avoiding hypoglycemic episodes and optimising glycemic control
• 7.4 Improving compliance and reducing the burden of insulin therapy
• 7.5 High financial cost of T1D management

8 R&D Strategies

• 8.1 Overview
  • 8.1.1 Immunomodulatory therapies: addressing autoimmune pathogenesis
  • 8.1.2 Advanced drug delivery systems and glucose-responsive insulins
  • 8.1.3 Regenerative medicine: pursuing curative therapies
• 8.2 Clinical trials design
  • 8.2.1 Study design - adaptive clinical trials and comprehensive frameworks
  • 8.2.2 Digital health integration
  • 8.2.3 Model-based simulations

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising drugs in clinical development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive assessment
  • 10.2.1 Insulin therapies
  • 10.2.2 Non-insulin therapies

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-making trends

12 Market Outlook

• 12.1 Global markets
  • 12.1.1 Forecast
  • 12.1.2 Drivers and barriers - global issues
• 12.2 US
  • 12.2.1 Forecast
  • 12.2.2 Key events
  • 12.2.3 Drivers and barriers
• 12.3 EU
  • 12.3.1 Forecast
  • 12.3.2 Key events
  • 12.3.3 Drivers and barriers
• 12.4 Japan
  • 12.4.1 Forecast
  • 12.4.2 Key events
  • 12.4.3 Drivers and barriers

13 Appendix

• 13.1 Bibliography
• 13.2 Abbreviations
• 13.3 Methodology
  • 13.3.1 Forecasting methodology
• 13.4 Primary research - KOLs interviewed for this report
  • 13.4.1 KOLs
• 13.5 Primary research - prescriber survey
• 13.6 About the authors
  • 13.6.1 Analyst
  • 13.6.2 Therapy Area Director
  • 13.6.3 Vice President of Disease Intelligence and Epidemiology
  • 13.6.4 Global Head of Pharma Research, Analysis, and Competitive Intelligence
• About GlobalData
• Contact Us